ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland
New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer and Nutrition in Zurich shows that palonosetron, a second generation 5-HT3 receptor antagonist, warrants adequate caloric intake in oncology patients receiving high emetogenic chemotherapy (HEC). The result comes from an innovative study conducted in the Oncology Institute of Ospedale V. Fazzi of Lecce, Italy, by the research team of Dr. Vito Lorusso. The findings confirmed the efficacy of a single dose of palonosetron and dexamethasone to control chemotherapy-induced nausea and vomiting (CINV) episodes in patients treated with HEC (cisplatin and/or epirubicin and/or iphosphamide) for soft tissue sarcoma: 76% of the patients achieved complete response (no vomiting, no use of rescue medication), 74% complete control (complete response and no more than mild nausea), in the 7-day period following chemotherapy, after palonosetron treatment.
Moreover, the results demonstrated that patients with no vomiting and
without nausea had a median daily food intake of 1500 Kcal and 1600 Kcal in
the acute and delayed period respectively, which is an adequate caloric
consumption. "Palonosetron not only confirms its ability to control nausea,"
Dr. Lorusso commented. "But considering the relevance of a correct
nutritional status for cancer patients, it also demonstrates to allow an
adequate caloric consumption, in the 7 day period following chemotherapy.
Moreover this benefit prolonged over the monitored period, allowing patients
to avoid chemot
|SOURCE Helsinn Healthcare SA|
Copyright©2009 PR Newswire.
All rights reserved